Success Metrics

Clinical Success Rate
85.6%

Based on 155 completed trials

Completion Rate
86%(155/181)
Active Trials
4(2%)
Results Posted
29%(45 trials)
Terminated
26(12%)

Phase Distribution

Ph early_phase_1
1
0%
Ph phase_1
37
16%
Ph phase_2
43
19%
Ph phase_3
2
1%
Ph phase_4
1
0%
Ph not_applicable
16
7%

Phase Distribution

38

Early Stage

43

Mid Stage

3

Late Stage

Phase Distribution100 total trials
Early Phase 1First-in-human
1(1.0%)
Phase 1Safety & dosage
37(37.0%)
Phase 2Efficacy & side effects
43(43.0%)
Phase 3Large-scale testing
2(2.0%)
Phase 4Post-market surveillance
1(1.0%)
N/ANon-phased studies
16(16.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

82.0%

155 of 189 finished

Non-Completion Rate

18.0%

34 ended early

Currently Active

4

trials recruiting

Total Trials

225

all time

Status Distribution
Active(6)
Completed(155)
Terminated(34)
Other(30)

Detailed Status

Completed155
unknown30
Terminated26
Withdrawn8
Active, not recruiting3
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
225
Active
4
Success Rate
85.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.0%)
Phase 137 (37.0%)
Phase 243 (43.0%)
Phase 32 (2.0%)
Phase 41 (1.0%)
N/A16 (16.0%)

Trials by Status

not_yet_recruiting21%
active_not_recruiting31%
completed15569%
terminated2612%
recruiting10%
unknown3013%
withdrawn84%

Recent Activity

Clinical Trials (225)

Showing 20 of 225 trialsScroll for more
NCT00628368Not Applicable

Biological Factors in Predicting Response to Treatment in Patients With Esophageal Cancer or Rectal Cancer

Completed
NCT00897117

Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

Recruiting
NCT00977457Phase 1

Genetic Testing in Predicting Biomarkers of Recurrence in Patients With Prostate Cancer Undergoing Surgery

Active Not Recruiting
NCT00812669Phase 2

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Completed
NCT00898508

Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease

Completed
NCT00873275Phase 1

Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer

Completed
NCT06959017Not Applicable

Diffrence in Thromboprofilaksis in Elderly Ostoepenic Hip Fractures According to Mobility Status by Genetic Analysis

Active Not Recruiting
NCT00544414Phase 2

Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer

Completed
NCT06302556

The Role of Immune Checkpoints in Lung Transplant (ILTRA)

Not Yet Recruiting
NCT00736450Early Phase 1

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Terminated
NCT00617799

Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma

Completed
NCT00499083Phase 2

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Completed
NCT01336933Phase 2

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Completed
NCT00665457Phase 2

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

Terminated
NCT00900224

Studying Tissue and Blood Samples From Patients With Acute Myeloid Leukemia

Unknown
NCT00898456

Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia

Active Not Recruiting
NCT00770185Phase 2

Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer

Completed
NCT01267812Phase 2

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Completed
NCT04445532

Hepatobiliary Tumors Tissue Samples Acquisition

Unknown
NCT00641030Phase 1

Clofarabine and High-Dose Melphalan Followed by Donor Stem Cell Transplant in Patients With Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Myelodysplastic Syndromes

Completed

Drug Details

Intervention Type
GENETIC
Total Trials
225